MTSL Companies Deliver The Goods In Mid-Issue Update
BIOINVEST BREAKING NEWS - In light of the historic, market selloff due to the coronavirus, we thought it was important to update subscribers with a brief summary of the highlights of our recommended...
View ArticleVaxart (ZXRT) — VXRT’s Oral Vaccine for COVID-19 Poised to Enter Human Testing
BIOINVEST BREAKING NEWS – Special Update -- NEW RECOMMENDATION: Vaxart (VXRT) - VXRT’s Oral Vaccine for COVID-19 Poised to Enter Human Testing. Read more... To access this post, you must have an active...
View ArticleZynerba (ZYNE) — Zygel Topline Results Fall Short of Statistical...
BIOINVEST BREAKING NEWS – Special Update – #ZYNERBA – ZYNE’s stock is down significantly this morning after reporting disappointing top line results from the 14-week pivotal CONNECT-FX (Clinical study...
View ArticleVaxart (VXRT) — Negating The Egregious NY Times Article
Special Update: Vaxart (VXRT) - Negating The Egregious NY Times Article - While we rarely rebut a short report or bear raid on one of our recommendations, the The NY Times published one of the more...
View ArticleSangamo (SGMO) — (BMRN/SGMO) Surprise Roctavian CRL – Bad For BioMarin, Good...
BioInvest News - BMRN/SGMO - Surprise Roctavian CRL - Bad For BioMarin, Good For SGMO - This morning, the FDA issued a surprise Complete Response Letter for BioMarin’s Roctavian, its lead hemophilia A...
View ArticleBioMarin (BMRN) — (BMRN/SGMO) Surprise Roctavian CRL – Bad For BioMarin, Good...
BioInvest News - BMRN/SGMO - Surprise Roctavian CRL - Bad For BioMarin, Good For SGMO - This morning, the FDA issued a surprise Complete Response Letter for BioMarin’s Roctavian, its lead hemophilia A...
View ArticleMyovant (MYOV) — Regugolix HERO Data Equivalent But Not Superior to...
BIOINVEST BREAKING NEWS - MYOV announced results of an additional secondary endpoint from the Phase III HERO study evaluating relugolix in men with advanced prostate cancer. Relugolix did not achieve...
View ArticleAlkermes (ALKS) — FDA Advisory Committee Votes in Support of ALKS 3831 for...
BIOINVEST BREAKING NEWS - In late Breaking News, ALKS announced overwhelming and surprising positive votes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety...
View ArticleVaxart (VXRT) — Starts Phase I Dosing & Delivers Positive Hamster Challenge...
Special Update: Vaxart (VXRT) - VXRT has delivered two very good pieces of news - the Company has enrolled its first patient in the COVID vaccine study and also released uniformly positive hamster...
View ArticleEsperion (ESPR) — NEXLETOL Launch Stifled Under COVID
(ESPR) BioInvest News — Esperion reported financials ($3 million in net sales) after the close yesterday and the stock is under pressure today as the Company continues to struggle with the new drug...
View ArticleVaxart (VXRT) — Pfizer/BNTX COVID-19 Vaccine Shows Better-Than-Expected...
Special Update: Vaxart (VXRT) - Following up on key features and still questions on the exceptional >90% efficacy in the first Phase II/III trial of their mRNA COVID vaccine from Pfizer/BNTX. BUY...
View ArticleFive Prime (FPRX) — FPA144 Delivers Outstanding Top-Line Phase II Bema Data...
Special Update: Five Prime (FPRX) - FPRX announced excellent topline results from the global, randomized, double-blind placebo-controlled Phase II FIGHT trial. Read more... To access this post, you...
View ArticleNektar (NKTR) — NKTR Inks Two Partners, Merck & SFJ Pharmaceuticals...
BIOINVEST BREAKING NEWS - This morning NKTR announced that it has signed two deals to advance BEMPEG combos - one with Merck and the other with SFJ. The first is a Phase II/III trial of BEMPEG in...
View ArticleFive Prime (FPRX) — AMGN To Acquire Five Prime for $38, TARGET PRICE of $33...
Special Update: Five Prime (FPRX) - This morning, FPRX announced that it is being bought by Amgen for $38 per share (~80% premium to yesterday’s closing price), representing an equity value of...
View ArticleAcadia (ACAD) — FDA Bombs ACAD With Undisclosed sNDA Deficiencies, Lowering...
Special Update: Acadia (ACAD) - In another FDA surprise, after the close, the Agency notified ACAD that it has identified deficiencies in the dementia related psychosis (DRP) sNDA for pimavanserin that...
View ArticleCelldex (CLDX) — Delivers Outstanding Phase 1b Data
BIOINVEST BREAKING NEWS - Celldex (CLDX) Delivers Outstanding Phase 1b Data, 19 of 20 Urticarial Patients Demonstrate Complete Response After Single Dose of CDX-0159, Raising BUY to 47 (from 30) and...
View ArticleCelldex (CLDX) — CDX-0159 – The Mast Cell Warrior (New Recommendation)
BIOINVEST NEW RECOMMENDATION - Celldex (CLDX) We are initiating coverage of Celldex Therapeutics (CLDX, $12) with a BUY under $15 and a $30 TARGET PRICE. In our view, CDX-0159, the Company’s anti-C-KIT...
View ArticleSangamo (SGMO) — SGMO’s PhaseI/II Fabry Disease Data Looks Great
BioInvest News - SGMO’s PhaseI/II Fabry Disease Data Looks Great - In it’s quarterly update, SGMO delivered news across multiple clinical programs today with the stock reacting positively to the...
View ArticlePrecigen (PGEN) — R&D Update Highlights Depth & Breadth of Novel Pipeline – BUY
BIOINVEST BREAKING NEWS - Precigen held a virtual R&D presentation yesterday, updating data on five clinical trials from the novel Ultra-CAR-T and AdenoVerse platforms. The company has delivered...
View ArticleAlkermes (ALKS) — ALKS Blindsided by JNJ Early Termination of Invega Sustenna...
Alkermes (ALKS) — ALKS was blindsided by JNJ after the close yesterday received notices of partial early termination for two license agreements with Janssen Pharmaceutica N.V., a subsidiary of JNJ....
View Article
